background image dots background image dots darker background image dots red

The OnKure team is comprised of proven drug discovery and development scientists who are combining their cancer biology, medicinal chemistry and development expertise to create a robust pipeline of new candidates. Our leadership team made significant contributions to the success of Array BioPharma, a highly renowned small molecule drug discovery company, which was acquired by Pfizer in 2019. We are confident in our ability to repeat past successes, including the discovery of several marketed oncology drugs. Our drug discovery and development acumen positions us well to write the next chapter in oncology precision medicines.

Our Criteria for Target Selection

Icon for Ability to leverage our team’s expertise

Ability to leverage our team’s expertise

Icon for Opportunity for portfolio synergy

Opportunity for portfolio synergy

Icon for Compelling biological validation

Compelling biological validation

Icon for Target structure can be determined (structural enablement)

Target structure can be determined (structural enablement)

Icon for Potential for best-in-class drug candidate

Potential for best-in-class drug candidate

Icon for Clinical proof of concept path identified

Clinical proof of concept path identified